An approved medicine has been associated with post-marketing adverse event case reports following administration of the drug in the eye. Novartis is seeking plausible hypotheses for these observations based upon publicly available information.
Novartis is launching this Ideation Challenge for a recently introduced drug in the market that is linked with post-marketing adverse event case reports following administration of the drug in the human eye. A small number of patients experienced adverse events termed as “retinal vasculitis” and/or “retinal vascular occlusion” that may result in severe vision loss and/or decreased visual acuity. Typically, these events occurred in the presence of intraocular inflammation (IOI). This is a brainstorming activity to help examine the potential root cause of these reported post-marketing adverse events with a particular interest in identifying parallels from life or physical sciences to provide relevant and plausible insights as to why these rare reported post-marketing adverse events have occurred. For more information on the ongoing efforts of Novartis, please visit https://www.novartis.com/news/media-releases/us-fda-approves-updated-novartis-beovu-label-include-additional-safety-information.
Awards:-
This is an Ideation Challenge, which has the following unique features:
- There is a guaranteed award. The award(s) will be paid to the best submission(s) as solely determined by the Seeker. The total payout will be $20,000, with at least one award being no smaller than $10,000 and no award being smaller than $2,500, subject to your acceptance of the terms & conditions set forth in the Challenge Specific Agreement.
- By submitting a proposal, the Solver grants to the Seeker a royalty-free, perpetual, and non-exclusive license to use any information included in this proposal, including for promotional purposes. The Solver further agrees to give the Seeker an exclusive option to obtain an exclusive license in respect of all intellectual property rights in this proposal. The period of time for Seeker to exercise the option shall be for 90 days subsequent to the payment of the guaranteed award. The Seeker shall have the right to exercise the exclusive option at the sole discretion of Seeker. Upon exercising the exclusive option, the Seeker shall pay the Solver a one-time payment. For the avoidance of doubt, this one-time payment is in addition to the aforementioned guaranteed award. If Seeker exercises its option, the Solver commits to execute documents sufficient to perfect ownership of all intellectual property rights in the proposal at no additional costs to Seeker. Seeker shall pay any incidental costs associated with perfecting such ownership.
Deadline:- 20-09-2020
